Number of colposcopic cervical biopsies and diagnosis of cervical intraepithelial neoplasia: a prospective study

Objective: To define the relationship between the number of cervical colposcopic biopsies performed on a patient and the diagnosis of each grade of cervical intraepithelial neoplasia (CIN). Methods: Patients who underwent a colposcopy and biopsy between January and June 2018 in an Italian second-level check-point for cervical cancer screening were prospectively enrolled in the study. Cervical punch biopsies were performed on abnormal acetowhite areas that were identified by colposcopy and endocervical sampling was performed if needed. The number of cervical biopsies per patient was recorded along with the following parameters: type of transforming zone, colposcopic grading, Pap smear result, the patient's age, and endocervical sampling. All parameters were included in multivariable models. The dependent variable was a diagnosis of CIN-0/1, CIN-2, or CIN-3. Results: Independently of other variables, a Pap test result of atypical squamous cells—cannot be excluded H-SIL (ASC-H), atypical glandular cells, not otherwise specified (AGC-NOS), or high grade squamous intraepithelial lesion (H-SIL) is associated with reduced odds of a CIN-0 or CIN-1 diagnosis. More than one cervical biopsy per patient is associated with reduced odds of a CIN-0 or CIN-1 diagnosis whereas three or four biopsies is associated with increased odds of a CIN-2 diagnosis. A Pap test result of HSIL, ASC-H, or AGC-NOS is the only variable that increased the odds of a CIN-3 diagnosis. Discussion: A greater number of cervical biopsies performed on a patient increases the likelihood of diagnosing a CIN-2 but has no effect on the diagnoses of CIN-0/1 or CIN-3.

Cervical biopsy; Colposcopy; Cervical intraepithelial neoplasia

[1] Chrysostomou AC, Stylianou DC, Constantinidou A, Kostrikis LG. Cervical Cancer Screening Programs in Europe: the Transition towards HPV Vaccination and Population-Based HPV Testing. Viruses. 2018; 10: 729.

[2] Perkins RB, Guido RS, Castle PE, Chelmow D, Einstein MH, Garcia F, et al. 2019 ASCCP Risk-Based Management Consensus Guidelines for Abnormal Cervical Cancer Screening Tests and Cancer Precursors. Journal of Lower Genital Tract Disease. 2020; 24: 102–131.

[3] Luesley D, Bowring J, Brady J, Cruickshank M, Cruickshank D, Cullimore J, et al. NHS cervical screening programme. Colposcopy and programme management. 2016. Available at: https://www.bsccp.org.uk/assets/file/uploads/resources/NHSCSP_20_Co lposcopy_and_Programme_Management_(3rd_Edition)_(2).pdf(Accessed: 15 April 2019).

[4] Bentley J. Colposcopic management of abnormal cervical cytology and histology. Journal of Obstetrics and Gynaecology Canada. 2012; 34: 1188–1202.

[5] Broutet N, Dangou JM, Fadhil I, Lazdane G, Luciana S, Mathur A, et al. WHO Guidelines. WHO guidelines for screening and treatment of precancerous lesions for cervical cancer prevention. 2013. Available at: https://apps.who.int/iris/bitstream/handle /10665/94830/9789241548694_eng.pdf;jsessionid=A8870178F 527BCA7612DAFBACD09B5CB sequence=1 (Accessed: 15 April 2019).

[6] Agarossi A, Barbero M, Cattani P, Ciavattini A, Clemente N, Cristoforoni P, et al. Raccomandazioni SICPCV 2019. Gestione colposcopica delle lesioni del basso tratto genitale. 2019. Available at: http://www.colposcopiaitaliana.it/pdf07/Capitolo_1_Ge stione_delle_lesioni_citologiche.pdf (Accessed: 15 April 2019).

[7] Kyrgiou M, Athanasiou A, Kalliala IEJ, Paraskevaidi M, Mitra A, Martin-Hirsch PP, et al. Obstetric outcomes after conservative treatment for cervical intraepithelial lesions and early invasive disease. Cochrane Database of Systematic Reviews. 2017; 11: CD012847.

[8] Kolben TM, Etzel LT, Bergauer F, Hagemann I, Hillemanns P, Repper M, et al. A randomized trial comparing limited-excision conisation to Large Loop Excision of the Transformation Zone (LLETZ) in cervical dysplasia patients. Journal of Gynecologic Oncology. 2019; 30: e42.

[9] Sopracordevole F, Carpini GD, Del Fabro A, Serri M, Alessandrini L, Buttignol M, et al. Role of Close Endocervical Margin in Treatment Failure after Cervical Excision for Cervical Intraepithelial Neoplasia: a Retrospective Study. Archives of Pathology & Laboratory Medicine. 2019; 143: 1006–1011.

[10] Kawano K, Tsuda N, Nishio S, Yonemoto K, Tasaki K, Tasaki R, et al. Identification of appropriate cone length to avoid positive cone margin in high grade cervical intraepithelial neoplasia. Journal of Gynecologic Oncology. 2016; 27: e54.

[11] Bae HS, Chung YW, Kim T, Lee KW, Song JY. The appropriate cone depth to avoid endocervical margin involvement is dependent on age and disease severity. Acta Obstetricia Et Gynecologica Scandinavica. 2013; 92: 185–192.

[12] Papoutsis D, Rodolakis A, Mesogitis S, Sotiropoulou M, Antsaklis A. Appropriate cone dimensions to achieve negative excision margins after large loop excision of transformation zone in the uterine cervix for cervical intraepithelial neoplasia. Gynecologic and Obstetric Investigation. 2013; 75: 163–168.

[13] Stoler MH, Schiffman M. Interobserver reproducibility of cervical cytologic and histologic interpretations: realistic estimates from the ASCUS-LSIL Triage Study. Journal of the American Medical Association. 2001; 285: 1500–1505.

[14] Tainio K, Athanasiou A, Tikkinen KAO, Aaltonen R, Cárdenas J, Hernándes, et al. Clinical course of untreated cervical intraepithelial neoplasia grade 2 under active surveillance: systematic review and meta-analysis. British Medical Journal. 2018; 360: k499.

[15] Kang WD, Choi HS, Kim SM. Is vaccination with quadrivalent HPV vaccine after loop electrosurgical excision procedure effective in preventing recurrence in patients with high-grade cervical intraepithelial neoplasia (CIN2–3)? Gynecologic Oncology. 2013; 130: 264–268.

[16] Karimi-Zarchi M, Allahqoli L, Nehmati A, Kashi AM, Taghipour-Zahir S, Alkatout I. Can the prophylactic quadrivalent HPV vaccine be used as a therapeutic agent in women with CIN? a randomized trial. BMC Public Health. 2020; 20: 274.

[17] Bornstein J, Bentley J, Bösze P, Girardi F, Haefner H, Menton M, et al. 2011 colposcopic terminology of the International Federation for Cervical Pathology and Colposcopy. Obstetrics and Gynecology. 2012; 120: 166–172.

[18] Nayar R, Wilbur DC. The Pap test and Bethesda 2014. Cancer Cytopathology. 2015; 123: 271–281.

[19] Bondi A, Boselli F, Cristiani P, Giorgi Rossi P, Manfredi M, Nigrisoli E, et al. Protocollo diagnostico terapeutico dello screening per la prevenzione dei tumori del collo dell’utero nella regione Emilia Romagna. 2014. Available at: https://salute.regione.emilia-romagna.it/screening/tumori-fem minili/documentazione/report-linee-guida-manuali-operativi /protocollo-diagnostico-terapeutico-dello-screening-per-la-p revenzione-dei-tumori-del-collo-dellutero (Accessed: 15 April 2019).

[20] Liu AH, Walker J, Gage JC, Gold MA, Zuna R, Dunn ST, et al. Di-agnosis of Cervical Precancers by Endocervical Curettage at Colposcopy of Women with Abnormal Cervical Cytology. Obstetrics & Gynecology. 2017; 130: 1218–1225.

[21] Hu S, Zhang W, Li S, Li N, Huang M, Pan Q, et al. Pooled analysis on the necessity of random 4-quadrant cervical biopsies and endocervical curettage in women with positive screening but negative colposcopy. Medicine. 2017; 96: e6689.

[22] Pretorius RG, Zhang W, Belinson JL, Huang M, Wu L, Zhang X, et al. Colposcopically directed biopsy, random cervical biopsy, and endocervical curettage in the diagnosis of cervical intraepithelial neoplasia II or worse. American Journal of Obstetrics and Gynecology. 2004; 191: 430–434.

[23] Gage JC, Hanson VW, Abbey K, Dippery S, Gardner S, Kubota J, et al. Number of cervical biopsies and sensitivity of colposcopy. Obstetrics and Gynecology. 2006; 108: 264–272.

[24] Underwood M, Arbyn M, Parry-Smith W, De Bellis-Ayres S, Todd R, Redman CWE, et al. Accuracy of colposcopy-directed punch biopsies: a systematic review and meta-analysis. BJOG: An International Journal of Obstetrics and Gynaecology. 2012; 119: 1293–1301.

[25] Goksedef BPC, Akbayir O, Numanoglu C, Corbacioglu A, Guraslan H, Bakir LV, et al. Evaluation of endocervical canal in women with minimal cervical cytological abnormalities. Journal of Lower Genital Tract Disease. 2013; 17: 261–266.

[26] Suwansura P, Darojn D. Accuracy of Cervical Visual Inspection with Acetic Acid Guide for 4-Quadrant Random Cervical Biopsies by General Practitioners in Women with Abnormal Pap Smears. Asian Pacific Journal of Cancer Prevention. 2017; 18: 2063–2066.

[27] Pretorius RG, Belinson JL, Burchette RJ, Hu S, Zhang X, Qiao Y. Regardless of skill, performing more biopsies increases the sensitivity of colposcopy. Journal of Lower Genital Tract Disease. 2011; 15: 180–188.

[28] Zuchna C, Hager M, Tringler B, Georgoulopoulos A, Ciresa-Koenig A, Volgger B, et al. Diagnostic accuracy of guided cervical biopsies: a prospective multicenter study comparing the histopathology of simultaneous biopsy and cone specimen. American Journal of Obstetrics and Gynecology. 2010; 203: 321.e1–321. e6.

[29] Wentzensen N, Walker JL, Gold MA, Smith KM, Zuna RE, Mathews C, et al. Multiple biopsies and detection of cervical cancer precursors at colposcopy. Journal of Clinical Oncology. 2015; 33: 83–89.

[30] Silver MI, Gage JC, Schiffman M, Fetterman B, Poitras NE, Lorey T, et al. Clinical Outcomes after Conservative Management of Cervical Intraepithelial Neoplasia Grade 2 (CIN2) in Women Ages 21–39 Years. Cancer Prevention Research. 2018; 11: 165–170.

[31] Skorstengaard M, Lynge E, Suhr J, Napolitano G. Conservative management of women with cervical intraepithelial neoplasia grade 2 in Denmark: a cohort study. BJOG: An International Journal of Obstetrics & Gynaecology. 2020; 127: 729–736.

[32] Myriokefalitaki E, Redman CWE, Potdar N, Pearmain P, Moss EL. The Use of the Colposcopically Directed Punch Biopsy in Clinical Practice: a Survey of British Society of Colposcopy and Cervical Pathology (BSCCP)-Accredited Colposcopists. Journal of Lower Genital Tract Disease. 2016; 20: 234–238.